The estimated Net Worth of Carol Burt is at least $6.52 Milhão dollars as of 22 November 2021. Ms. Burt owns over 1,500 units of Resmed stock worth over $3,311,987 and over the last 14 years she sold RMD stock worth over $2,869,045. In addition, she makes $342,427 as Independent Director at Resmed.
Carol has made over 9 trades of the Resmed stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 1,500 units of RMD stock worth $390,000 on 22 November 2021.
The largest trade she's ever made was selling 10,000 units of Resmed stock on 2 March 2020 worth over $1,649,000. On average, Carol trades about 574 units every 50 days since 2010. As of 22 November 2021 she still owns at least 13,095 units of Resmed stock.
You can see the complete history of Ms. Burt stock trades at the bottom of the page.
Carol J. Burt serves as Independent Director of the Company. s. Burt has been a principal of Burt-Hilliard Investments since 2008, and since January 2013, has served as a senior advisor and operating council member to Consonance Capital Partners, a New York-based private equity firm focused on investing in the U.S. healthcare industry. In addition to ResMed, Ms. Burt serves on the boards of IQVIA (NYSE: IQV), a global leader in healthcare information, innovative technology solutions, and contract research services where she serves on the audit committee; Global Medical Response, a privately-held medical transportation, fire, integrated health solutions and disaster response company where she serves on the audit committee and chairs the compliance committee; and WellDyne, a privately held pharmacy benefit management company, where she chairs the audit committee. Previously, she served on the public boards of Envision Healthcare, Inc., WellCare Health Plans, Inc., Vanguard Health Systems, Inc., Transitional Hospitals Corporation, and privately held KEPRO. Ms. Burt was formerly an executive of WellPoint, Inc., now Anthem, Inc (NYSE: ANTM), where she served from 1997 to 2007, most recently as WellPoint’s senior vice president of corporate finance and development. She was a member of the executive team that built WellPoint from a small single-state Blue Cross plan to one of the country’s leading health benefits companies with nationwide reach, revenues of $61 billion, and market cap of $50 billion. She was responsible for Wellpoint’s corporate strategic planning and execution; mergers and acquisitions; strategic investments; finance, treasury, and real estate management; financial services and international insurance businesses. Before WellPoint, Ms. Burt was senior vice president and treasurer of American Medical Response, overseeing its sale to Laidlaw, Inc. Previously, she spent 16 years at Chase Securities, Inc., now JP Morgan Chase & Co (NYSE: JPM), most recently as man
As the Independent Director of Resmed, the total compensation of Carol Burt at Resmed is $342,427. There are 15 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.
Carol Burt is 62, she's been the Independent Director of Resmed since 2013. There are 5 older and 16 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.
Carol's mailing address filed with the SEC is 9001 SPECTRUM CENTER BLVD, , SAN DIEGO, CA, 92123.
Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, eDavid Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.
at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
Resmed executives and other stock owners filed with the SEC include: